glimepiride has been researched along with Glucose Intolerance in 9 studies
glimepiride: structure given in first source
Glucose Intolerance: A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is a biomarker and mediator of cardiovascular disease in patients with impaired glucose tolerance (IGT) or diabetes mellitus (DM)." | 9.17 | Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. ( Imaizumi, T; Mizoguchi, M; Tahara, A; Tahara, N; Yamagishi, S, 2013) |
| "Our study indicated that pioglitazone decreased the visceral fat volume and its metabolic activity in patients with impaired glucose tolerance or type 2 diabetes mellitus." | 9.17 | Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus. ( Abe, T; Fukumoto, Y; Honda, A; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mizoguchi, M; Narula, J; Nitta, Y; Tahara, A; Tahara, N; Yamagishi, S, 2013) |
| "The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging." | 9.15 | Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011) |
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is a biomarker and mediator of cardiovascular disease in patients with impaired glucose tolerance (IGT) or diabetes mellitus (DM)." | 5.17 | Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. ( Imaizumi, T; Mizoguchi, M; Tahara, A; Tahara, N; Yamagishi, S, 2013) |
| "Our study indicated that pioglitazone decreased the visceral fat volume and its metabolic activity in patients with impaired glucose tolerance or type 2 diabetes mellitus." | 5.17 | Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus. ( Abe, T; Fukumoto, Y; Honda, A; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mizoguchi, M; Narula, J; Nitta, Y; Tahara, A; Tahara, N; Yamagishi, S, 2013) |
| "The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging." | 5.15 | Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011) |
| "With single doses, there was a clear dose-response relationship for the reduction in AUC, with a statistically significant difference only between placebo (mean 1981, 95% confidence intervals (CI) 1883-2078) and 2 mg glimepiride (mean 1763, 95% CI 1665-1861)." | 2.70 | The NEPI antidiabetes study (NANSY). 1: short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. ( Lindblad, U; Lindwall, K; Melander, A; Ranstam, J; Sjöstrand, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Niedowicz, DM | 1 |
| Özcan, S | 1 |
| Nelson, PT | 1 |
| Tahara, N | 3 |
| Yamagishi, S | 3 |
| Mizoguchi, M | 3 |
| Tahara, A | 3 |
| Imaizumi, T | 3 |
| Kodama, N | 2 |
| Honda, A | 1 |
| Nitta, Y | 2 |
| Kaida, H | 2 |
| Ishibashi, M | 2 |
| Abe, T | 1 |
| Ikeda, H | 2 |
| Narula, J | 2 |
| Fukumoto, Y | 1 |
| Ramanathan, RP | 1 |
| Arbeláez, AM | 1 |
| Cryer, PE | 1 |
| Tawakol, A | 1 |
| Finn, AV | 1 |
| Oba, T | 1 |
| Mawatari, K | 1 |
| Yasukawa, H | 1 |
| Hayabuchi, N | 1 |
| Harada, H | 1 |
| Marwick, TH | 1 |
| Kawamori, R | 1 |
| Lindblad, U | 1 |
| Lindwall, K | 1 |
| Sjöstrand, A | 1 |
| Ranstam, J | 1 |
| Melander, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study[NCT02999841] | Phase 4 | 100 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | ||
| Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT[NCT00722631] | 70 participants (Actual) | Interventional | 2007-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for glimepiride and Glucose Intolerance
| Article | Year |
|---|---|
[Therapies for newly-onset diabetic patients].
Topics: Acarbose; Cyclohexanes; Diabetes Mellitus, Type 2; Diet Therapy; Enzyme Inhibitors; Exercise Therapy | 2005 |
5 trials available for glimepiride and Glucose Intolerance
| Article | Year |
|---|---|
Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes.
Topics: Aged; Aged, 80 and over; Arginine; Diabetes Mellitus, Type 2; Female; Fibronectins; Glucose Intolera | 2013 |
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglu | 2013 |
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglu | 2013 |
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglu | 2013 |
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglu | 2013 |
Partial inhibition of insulin secretion results in glucose intolerance but not hyperglucagonemia.
Topics: Adult; Blood Glucose; C-Peptide; Diazoxide; Female; Glucagon; Glucose Intolerance; Humans; Hypoglyce | 2011 |
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Aortography; Biomarkers; Blood Glucose; C-Reactive | 2011 |
The NEPI antidiabetes study (NANSY). 1: short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose.
Topics: Blood Glucose; Body Constitution; Body Mass Index; Cholesterol; Dose-Response Relationship, Drug; Do | 2001 |
3 other studies available for glimepiride and Glucose Intolerance
| Article | Year |
|---|---|
Glimepiride Administered in Chow Reversibly Impairs Glucose Tolerance in Mice.
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Female; Gluconeogenes | 2018 |
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Art | 2011 |
Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?
Topics: Anti-Inflammatory Agents; Aortic Diseases; Aortography; Carotid Artery Diseases; Diabetes Mellitus, | 2011 |